Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Clotting factors: Clinical biochemistry and their roles as plasma enzymes.

Winter WE, Greene DN, Beal SG, Isom JA, Manning H, Wilkerson G, Harris N.

Adv Clin Chem. 2020;94:31-84. doi: 10.1016/bs.acc.2019.07.008. Epub 2019 Oct 18. Review.

PMID:
31952574
2.

Recent advances in computational modeling of fibrin clot formation: A review.

Yesudasan S, Averett RD.

Comput Biol Chem. 2019 Dec;83:107148. doi: 10.1016/j.compbiolchem.2019.107148. Epub 2019 Nov 10. Review.

PMID:
31751883
3.

Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays.

Wakui M, Fujimori Y, Nakamura S, Kondo Y, Kuroda Y, Oka S, Nakagawa T, Katagiri H, Murata M.

J Clin Pathol. 2019 Dec;72(12):817-824. doi: 10.1136/jclinpath-2019-205922. Epub 2019 Jul 31.

PMID:
31366633
4.

Clot activators do not expedite the time to predict massive transfusion in trauma patients analyzed with tissue plasminogen activator thrombelastography.

Walker CB, Moore EE, Kam A, Dexter-Meldrum J, Nydam TL, Chapman MP, Chandler J, Sauaia A, Barrett CD, Yaffe MB, Moore HB.

Surgery. 2019 Sep;166(3):408-415. doi: 10.1016/j.surg.2019.05.011. Epub 2019 Jun 21.

PMID:
31230841
5.

New Drug Treats Rare Blood Clotting Disorder.

Aschenbrenner DS.

Am J Nurs. 2019 Jun;119(6):24. doi: 10.1097/01.NAJ.0000559801.16738.00. No abstract available.

PMID:
31135424
6.

Effects of fibrinogen supplementation on clot formation in blood samples from cardiac surgery patients before and after tranexamic acid administration.

Waldén K, Shams Hakimi C, Jeppsson A, Karlsson M.

Transfus Med. 2019 Oct;29(5):319-324. doi: 10.1111/tme.12604. Epub 2019 May 22.

PMID:
31115109
7.

Oncogenes and Clotting Factors: The Emerging Role of Tumor Cell Genome and Epigenome in Cancer-Associated Thrombosis.

Tawil N, Bassawon R, Rak J.

Semin Thromb Hemost. 2019 Jun;45(4):373-384. doi: 10.1055/s-0039-1687891. Epub 2019 May 16. Review.

PMID:
31096313
8.

Tumors: Wounds That Do Not Heal-A Historical Perspective with a Focus on the Fundamental Roles of Increased Vascular Permeability and Clotting.

Dvorak HF.

Semin Thromb Hemost. 2019 Sep;45(6):576-592. doi: 10.1055/s-0039-1687908. Epub 2019 May 16. Review.

PMID:
31096305
9.

Future of platelet formulations with improved clotting profile: a short review on human safety and efficacy data.

Cancelas JA.

Transfusion. 2019 Apr;59(S2):1467-1473. doi: 10.1111/trf.15163. Review.

PMID:
30980736
10.

Evaluation of Blood Clot, Platelet-rich Plasma, Platelet-rich Fibrin, and Platelet Pellet as Scaffolds in Regenerative Endodontic Treatment: A Prospective Randomized Trial.

Ulusoy AT, Turedi I, Cimen M, Cehreli ZC.

J Endod. 2019 May;45(5):560-566. doi: 10.1016/j.joen.2019.02.002. Epub 2019 Mar 30.

PMID:
30935618
11.

Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B.

Preijers T, Schütte LM, Kruip MJHA, Cnossen MH, Leebeek FWG, van Hest RM, Mathôt RAA.

Ther Drug Monit. 2019 Apr;41(2):192-212. doi: 10.1097/FTD.0000000000000625. Review.

PMID:
30883513
12.

Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.

Woodruff S, Lee AYY, Carrier M, Feugère G, Abreu P, Heissler J.

J Thromb Thrombolysis. 2019 May;47(4):495-504. doi: 10.1007/s11239-019-01833-w.

13.

Impaired endogenous fibrinolysis at high shear using a point-of-care test in STEMI is associated with alterations in clot architecture.

Spinthakis N, Gue Y, Farag M, Ren G, Srinivasan M, Baydoun A, Gorog DA.

J Thromb Thrombolysis. 2019 Apr;47(3):392-395. doi: 10.1007/s11239-018-01799-1.

14.

Enamel matrix derivative stabilizes blood clot and improves clinical healing in deep pockets after flapless periodontal therapy: A Randomized Clinical Trial.

Graziani F, Gennai S, Petrini M, Bettini L, Tonetti M.

J Clin Periodontol. 2019 Feb;46(2):231-240. doi: 10.1111/jcpe.13074.

PMID:
30663788
15.

HRT tablets are associated with blood clot risk-but not patches, creams, or gels.

Kmietowicz Z.

BMJ. 2019 Jan 10;364:l157. doi: 10.1136/bmj.l157. No abstract available.

PMID:
30630821
16.

Concise Commentary: The Clot Thickens-Why Pylephlebitis Is One of the Most Feared Complications of Intra-abdominal Sepsis.

Stine JG.

Dig Dis Sci. 2019 Jun;64(6):1722-1723. doi: 10.1007/s10620-018-5440-6. No abstract available.

PMID:
30604377
17.

Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications.

Kearney KJ, Pechlivani N, King R, Tiede C, Phoenix F, Cheah R, Macrae FL, Simmons KJ, Manfield IW, Smith KA, Spurgeon BEJ, Naseem KM, Ariens RAS, McPherson MJ, Tomlinson DC, Ajjan RA.

Blood. 2019 Mar 14;133(11):1233-1244. doi: 10.1182/blood-2018-06-856195. Epub 2018 Dec 13.

18.

Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis.

Wakui M, Fujimori Y, Katagiri H, Nakamura S, Kondo Y, Kuroda Y, Nakagawa T, Shimizu N, Murata M.

J Clin Pathol. 2019 Mar;72(3):244-250. doi: 10.1136/jclinpath-2018-205517. Epub 2018 Dec 5.

PMID:
30518630
19.

Ageing in patients with chronic HIV infection: impact of hypercoagulation.

Kent SJ, Flexner C.

AIDS Res Ther. 2018 Nov 24;15(1):22. doi: 10.1186/s12981-018-0211-1. Review.

20.

Not all clots are created equal: a review of deficient thrombolysis with tissue plasminogen activator (tPA) in patients with metabolic syndrome.

Mosimah CI, Murray PJ, Simpkins JW.

Int J Neurosci. 2019 Jun;129(6):612-618. doi: 10.1080/00207454.2018.1550400. Epub 2018 Dec 27. Review.

PMID:
30465701

Supplemental Content

Loading ...
Support Center